Israel - hebraisk - Ministry of Health

comex ltd - pregnant mare serum gonadotrophin - אבקה להכנת תמיסה לזריקה - pregnant mare serum gonadotrophin 600 iu

Israel - hebraisk - Ministry of Health

comex ltd - pregnant mare serum gonadotrophin - אבקה להכנת תמיסה לזריקה - pregnant mare serum gonadotrophin 6000 iu

Israel - hebraisk - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 75 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

Israel - hebraisk - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 150 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

Israel - hebraisk - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israel - hebraisk - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Israel - hebraisk - Ministry of Health

organon pharma israel ltd., israel - ganirelix - תמיסה להזרקה - ganirelix 0.25 mg / 0.5 ml - ganirelix - ganirelix - the prevention of premature luteinsing hormone (lt) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Israel - hebraisk - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.

Israel - hebraisk - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Israel - hebraisk - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.